Wegovy Monitoring: What Your Provider Checks and When

The short version

The Wegovy label asks your provider to watch two things: heart rate, and blood glucose if you have diabetes. That is the whole required list. [1] Everything else you will read about here, weight, blood pressure, stomach tolerance, kidney function, mood, pregnancy status, is monitoring your provider chooses based on your own history and the problems Wegovy is known to cause. There is no single Well Revolution monitoring table for semaglutide yet. Your prescribing provider sets the schedule for you.

This article walks through each parameter in plain words: how often it is typically looked at, what result or symptom triggers a change, and what the change usually is. Where the label gives a number, we say so. Where it does not, we say the provider sets it. If you are still deciding whether Wegovy is right for you, start with the complete Wegovy guide and come back here once you are on treatment.

What the label actually requires

The FDA prescribing information for Wegovy names two monitoring parameters. The first is heart rate, because semaglutide can raise resting heart rate in some people. [1] The second is blood glucose, at baseline and then periodically, but only if you have diabetes, because Wegovy lowers glucose and can cause hypoglycemia when combined with insulin or a sulfonylurea. [1][2]

That is short on purpose. The label lists the serious reactions it wants providers alert to, pancreatitis, gallbladder disease, acute kidney injury, severe gastrointestinal reactions, ileus or bowel obstruction, hypoglycemia with diabetes drugs, fainting, and hypersensitivity, but it does not attach a lab schedule to each one. [1] For most of those, the monitoring is a return precaution: you know the symptoms, you report them, your provider acts. Routine calcitonin or thyroid ultrasound for the boxed thyroid warning is specifically described as of uncertain value, so it is not part of standard monitoring either. [1]

So when your provider checks more than heart rate and glucose, that is not the label. That is your provider tailoring monitoring to you. The rest of this article is that tailored list, parameter by parameter.

Weight and BMI

How often. At each dose step, then once per 3-month block once you are on a stable dose. [3] Well Revolution prescribes Wegovy injection in 3-month blocks, so the block review is a natural weigh-in point. [3] The full ladder is in the dosing schedule article.

Trigger. Two things get attention. Less loss than expected for where you are on the ladder, and loss that is faster than expected, particularly with poor food intake or dehydration signs. The trial average was about 15 percent of body weight over 68 weeks, and results vary widely, so your provider judges your trend against your own starting point, not against that number. [4]

Action. A dose or plan review. That can mean continuing up the ladder, holding at the current step longer, pausing the next step, or looking at the non-medication parts of the plan. A delayed step for any reason shifts your calendar. It does not change the ladder itself. [3]

Heart rate

How often. This is a label parameter. [1] Your provider will ask about it at check-ins and may ask you to record a resting pulse at home. The label does not set a specific interval, so the provider does. [1]

Trigger. A sustained rise in resting heart rate compared with your baseline, or new palpitations, a racing or pounding feeling at rest.

Action. Provider review. Depending on the size of the rise and your cardiac history, that can mean watching it, holding the dose step, or reducing the dose. Fainting is on the label's serious list, so a faint or near-faint is a same-day message, not a note for the next check-in. [1]

Blood pressure

How often. Not a label parameter. Weight loss tends to lower blood pressure, which matters most if you already take blood pressure medication. [5] Your provider sets whether and how often you check, usually at the same check-ins as weight.

Trigger. Readings running lower than usual, dizziness on standing, or lightheadedness, especially in the first weeks of a new step when eating and drinking may be reduced.

Action. Review of your blood pressure medications, and a reminder about fluids. [5] Dizziness and fatigue are common Wegovy side effects on their own, so the provider's job is to sort out which cause is in play. [1]

Blood glucose or A1c, if you have diabetes

How often. Label parameter. Glucose at baseline, then periodically. [1] The label does not fix the interval, so your provider sets it based on your diabetes regimen. If you are not diabetic, this parameter does not apply to you.

Trigger. Low blood sugar symptoms, shakiness, sweating, confusion, or low readings on your meter. The risk is real mainly when Wegovy is combined with insulin or a sulfonylurea, because those drugs push glucose down regardless of what you eat. [1]

Action. Adjusting those other drugs, not stopping Wegovy. This is one of the reasons your provider asks for a full medication list before your first dose. The before-you-start article covers what gets checked at baseline.

Gastrointestinal tolerance

How often. Every check-in, and every dose step. Nausea, vomiting, diarrhea, constipation, abdominal pain, heartburn, and bloating are the most common side effects. [1] They usually settle within the first 2 to 4 weeks of a step. [1] Smaller meals, slower eating, and steady hydration help most people through it. The nausea article has the practical detail.

Trigger. Signs of dehydration: persistent vomiting, not keeping fluids down, dark urine, very little urine, dizziness on standing, or diarrhea that does not settle. Severe or persistent abdominal pain is its own trigger, covered below.

Action. Hold or slow the step. In practice that means staying at the current dose longer, delaying the next increase, or briefly pausing while you rehydrate. The calendar shifts, the ladder does not change. [3] Dehydration is also how Wegovy leads to acute kidney injury, which is why this trigger gets a fast response rather than a wait-and-see. [1]

Gallbladder and pancreas symptoms

How often. There is no routine test here. This is a return precaution, meaning you are told the symptoms and asked to report them promptly.

Trigger. For pancreatitis: severe, persistent abdominal pain, often radiating to the back, with or without vomiting. [1] For gallbladder disease: pain in the upper right abdomen, especially after meals, fever, or yellowing of the skin or eyes. [1]

Action. Stop and message the same day. Pancreatitis and gallbladder disease are both on the label's serious list, and both need in-person evaluation rather than a chat reply. [1] A history of pancreatitis is a caution before starting, [1] which is one of the situations where your provider may want a specialist opinion first. If you have had your gallbladder removed, that changes the picture and is covered in this article.

Kidney function, where you are at risk

How often. Not a label parameter for everyone. If you have known kidney impairment, or a history of volume depletion, your provider may check kidney function at baseline and then at an interval they set. For a member with normal kidneys and no risk factors, most providers rely on the dehydration trigger above rather than scheduled labs.

Trigger. A dehydrating episode of vomiting or diarrhea, or a drop in kidney function on labs.

Action. Rehydration, a hold on the dose step, and repeat labs when the provider judges it necessary. Kidney impairment is a listed caution, so this is set per case. [1]

Eye symptoms, if you have diabetes

How often. Diabetic retinopathy is a listed caution. [1] If you have diabetes, your provider will ask whether you have retinopathy and whether you are up to date with eye exams. Wegovy does not add a new eye test to the schedule for non-diabetic members.

Trigger. Any new blurring, floaters, or vision change.

Action. Prompt eye evaluation. Rapid improvement in blood sugar can temporarily worsen existing retinopathy, so this is a report-it-now item, not something to wait on until the next block review. [1]

Mood changes

How often. Asked about at check-ins. Not a label monitoring parameter, but a reasonable question during any significant weight change and any new long-term medication.

Trigger. New or worsening low mood, anxiety, or any thoughts of self-harm.

Action. Provider review the same day for thoughts of self-harm. For milder changes, a conversation about whether the timing lines up with the medication and what support makes sense.

Pregnancy status

How often. Asked at every check-in if you could become pregnant. Wegovy is contraindicated in pregnancy for weight management, and the oral form is contraindicated while breastfeeding. [1]

Trigger. Planning a pregnancy, a missed period, or a positive test.

Action. If you are planning a pregnancy, the label says to stop Wegovy at least 2 months before. [1] If you find out you are pregnant on treatment, stop and message your provider the same day. The manufacturer runs a Wegovy Pregnancy Registry at 1-877-390-2760 that collects outcomes. [1] How and when to stop, and what happens after, is covered in the stopping article.

The boxed warning: what to report, not what to test

Wegovy carries a boxed warning about thyroid C-cell tumors seen in animal studies. Personal or family history of medullary thyroid carcinoma, or multiple endocrine neoplasia type 2, means you should not take it at all. [1] For everyone else, the label asks you to report a lump in the neck, trouble swallowing, shortness of breath, or hoarseness that does not go away. [1] It specifically says routine calcitonin or thyroid ultrasound is of uncertain value, so do not expect your provider to order those on a schedule. [1]

Putting it together

• Heart rate. Label parameter. [1] Checked at check-ins, interval set by provider. At trigger: provider review, possible hold or reduction.
• Glucose or A1c, diabetes only. Label parameter. [1] Baseline, then periodically. At trigger: adjust insulin or sulfonylurea.
• Weight and BMI. Provider-set. Each step, then each 3-month block. [3] At trigger: dose or plan review.
• Blood pressure. Provider-set. With weight, if on BP medication. At trigger: review BP drugs, fluids.
• GI tolerance. Provider-set. Every check-in and step. At trigger: hold or slow the step.
• Gallbladder and pancreas. Return precaution, no routine test. At trigger: same-day message, in-person evaluation.
• Kidney function. Provider-set for at-risk members. Baseline, then per provider. At trigger: rehydrate, hold, repeat labs.
• Eye symptoms, diabetes only. Provider-set. Asked at check-ins. At trigger: prompt eye evaluation.
• Mood. Provider-set. Asked at check-ins. At trigger: provider review.
• Pregnancy status. Label contraindication. [1] Every check-in if applicable. At trigger: stop, message same day.

The rhythm of check-ins that carries all of this is described in the follow-up schedule article. If you are unsure whether a symptom is a normal early effect or a stop-now warning, this guide sorts them.

What it costs with Well Revolution

$80 for the Limited Treatment Plan. If approved, you will receive a 90 day treatment plan with 7 days a week support. Perfect for first time patients who are trying it out.

Or $90 for the Unlimited Membership. If approved, you will receive a full year of care with 7 days a week support, plus unlimited prescriptions, lab tests, imaging orders, letters and referrals with same day care, cancel anytime, no fees. Perfect for established patients looking for full care.

Getting started with Well Revolution

Care is chat-based with a licensed provider, same day, no appointment needed. Message us and we confirm coverage in your state. If you are already on Wegovy and want a provider who sets a monitoring plan to your history rather than a template, that is exactly what the check-ins above are for.

References

1. Wegovy (semaglutide) prescribing information. Novo Nordisk, via FDA DailyMed, label updated 2026-06-18. DailyMed
2. Perreault L, et al. Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program. Diabetes Care, 2022. PubMed 35724304
3. Well Revolution semaglutide titration protocol, approved 2026-08-25 (internal)
4. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021. PubMed 33567185
5. Gudzune KA, Kushner RF. Medications for Obesity: A Review. JAMA, 2024. PubMed 39037780

Reviewed by PA Michael Rubio, US Medical Director